Literature DB >> 23607908

Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts.

K Takahashi1, H Imaeda, T Fujimoto, H Ban, S Bamba, T Tsujikawa, M Sasaki, Y Fujiyama, A Andoh.   

Abstract

Eotaxins induce the trafficking of eosinophils to the sites of inflammation via CC chemokine receptor 3 (CCR3). In this study, we investigated eotaxin-3/CC chemokine ligand 26 (CCL26) expression in the inflamed mucosa of patients with inflammatory bowel disease (IBD), and characterized the molecular mechanisms responsible for eotaxin-3 expression in human colonic myofibroblasts. Eotaxin-3 mRNA and protein expression was evaluated by real time-polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. Eotaxin-3 mRNA expression was elevated significantly in the active lesions of ulcerative colitis (UC) patients. Significant elevations were also observed in the active lesions of Crohn's disease (CD) patients, but this was significantly lower than that detected in the active UC lesions. There were no significant increases in the inactive lesions of UC or CD patients. Colonic myofibroblasts were identified as a major source of eotaxin-3 in the colonic mucosa, and interleukin (IL)-4 and IL-13 enhanced eotaxin-3 mRNA and protein expression significantly in these cells. There was a significant positive correlation between mucosal eotaxin-3 and IL-4 mRNA expression in the active lesions of IBD patients. The IL-4- and IL-13-induced eotaxin-3 mRNA expression was regulated by the signal transducer and activator of transcription-6 (STAT-6) and suppressor of cytokine signalling (SOCS)1-mediated pathways. Interferon (IFN)-γ acts as a negative regulator on the IL-4- and IL-13-induced eotaxin-3 expression via STAT-1 activation. Eotaxin-3 expression was elevated specifically in the active lesions of IBD, in particular UC. Eotaxin-3 derived from colonic myofibroblasts may play an important role in the pathophysiology of UC.
© 2013 British Society for Immunology.

Entities:  

Keywords:  IBD; SOCS; STAT; eosinophil

Mesh:

Substances:

Year:  2013        PMID: 23607908      PMCID: PMC3722932          DOI: 10.1111/cei.12117

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  Suppressors of cytokine signaling and immunity.

Authors:  Masato Kubo; Toshikatsu Hanada; Akihiko Yoshimura
Journal:  Nat Immunol       Date:  2003-12       Impact factor: 25.606

3.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease.

Authors:  Akira Andoh; Hiroyuki Kuzuoka; Tomoyuki Tsujikawa; Shiro Nakamura; Fumihito Hirai; Yasuo Suzuki; Toshiyuki Matsui; Yoshihide Fujiyama; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2012-05-11       Impact factor: 7.527

4.  Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts.

Authors:  T Okuno; A Andoh; S Bamba; Y Araki; Y Fujiyama; M Fujiyama; T Bamba
Journal:  Scand J Gastroenterol       Date:  2002-03       Impact factor: 2.423

5.  Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity.

Authors:  G A West; T Matsuura; A D Levine; J S Klein; C Fiocchi
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

Review 6.  IL-4/IL-13 signaling beyond JAK/STAT.

Authors:  H Jiang; M B Harris; P Rothman
Journal:  J Allergy Clin Immunol       Date:  2000-06       Impact factor: 10.793

7.  IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators.

Authors:  Mitsue Shimada; Akira Andoh; Kazunori Hata; Kazuhito Tasaki; Yoshio Araki; Yoshihide Fujiyama; Tadao Bamba
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

Review 8.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  Increased fecal eosinophil cationic protein in inflammatory bowel disease.

Authors:  A Berstad; B Børkje; B Riedel; S Elsayed; A Berstad
Journal:  Hepatogastroenterology       Date:  1993-06

10.  A human colonic tumor cell line that maintains vectorial electrolyte transport.

Authors:  K Dharmsathaphorn; J A McRoberts; K G Mandel; L D Tisdale; H Masui
Journal:  Am J Physiol       Date:  1984-02
View more
  13 in total

1.  Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice.

Authors:  Yang Li; Xiaojie Chu; Cunbao Liu; Weiwei Huang; Yufeng Yao; Ye Xia; Pengyan Sun; Qiong Long; Xuejun Feng; Kui Li; Xu Yang; Hongmei Bai; Wenjia Sun; Yanbing Ma
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

2.  Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour.

Authors:  R M Corcoran; P MacDonagh; F O'Connell; M E Morrissey; M R Dunne; R Argue; J O'Sullivan; D Kevans
Journal:  Dig Dis Sci       Date:  2022-03-14       Impact factor: 3.199

3.  Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart.

Authors:  Nicola L Diny; Xuezhou Hou; Jobert G Barin; Guobao Chen; Monica V Talor; Julie Schaub; Stuart D Russell; Karin Klingel; Noel R Rose; Daniela Čiháková
Journal:  Eur J Immunol       Date:  2016-10-25       Impact factor: 5.532

4.  Eosinophils and IL-33 Perpetuate Chronic Inflammation and Fibrosis in a Pediatric Population with Stricturing Crohn's Ileitis.

Authors:  Joanne C Masterson; Kelley E Capocelli; Lindsay Hosford; Kathryn Biette; Eóin N McNamee; Edwin F de Zoeten; Rachel Harris; Shahan D Fernando; Paul Jedlicka; Cheryl Protheroe; James J Lee; Glenn T Furuta
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

5.  Recombinant adenovirus containing hyper-interleukin-6 and hepatocyte growth factor ameliorates acute-on-chronic liver failure in rats.

Authors:  Dan-Dan Gao; Jia Fu; Bo Qin; Wen-Xiang Huang; Chun Yang; Bei Jia
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

6.  Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice.

Authors:  Marion T Kasaian; Karen M Page; Susan Fish; Agnes Brennan; Timothy A Cook; Karen Moreira; Melvin Zhang; Michael Jesson; Kimberly Marquette; Rita Agostinelli; Julie Lee; Cara M M Williams; Lioudmila Tchistiakova; Paresh Thakker
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 7.  Eosinophils in Autoimmune Diseases.

Authors:  Nicola L Diny; Noel R Rose; Daniela Čiháková
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

8.  Innate Lymphoid Cells Play a Pathogenic Role in Pericarditis.

Authors:  Hee Sun Choi; Taejoon Won; Xuezhou Hou; Guobao Chen; William Bracamonte-Baran; Monica V Talor; Ivana Jurčová; Ondrej Szárszoi; Lenka Čurnova; Ilja Stříž; Jody E Hooper; Vojtěch Melenovský; Daniela Čiháková
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

9.  Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.

Authors:  Timo Rath; Ulrike Billmeier; Fulvia Ferrazzi; Michael Vieth; Arif Ekici; Markus F Neurath; Raja Atreya
Journal:  Front Immunol       Date:  2018-07-31       Impact factor: 7.561

10.  Interleukin(IL)-36α and IL-36γ Induce Proinflammatory Mediators from Human Colonic Subepithelial Myofibroblasts.

Authors:  Toshihiro Kanda; Atsushi Nishida; Kenichiro Takahashi; Kentaro Hidaka; Hirotsugu Imaeda; Osamu Inatomi; Shigeki Bamba; Mitsushige Sugimoto; Akira Andoh
Journal:  Front Med (Lausanne)       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.